Búsqueda de noticias relacionadas a la acción BAYER SCHERING PH (ordenadas por fecha):

Makucell(TM) Appoints International Life Sciences Business Leader ... MarketWatch (press release) Dr. Scanlon was the CEO/Co-Founder of Melanoma Diagnostics, acquired by Myriad in 2010, and a Vice President at Berlex/Schering AG, where he was responsible for the development of medical products for diagnostics and small molecule projects in Europe, ... y más »

Makucell? Appoints International Life Sciences Business Leader and ... EON: Enhanced Online News (press release) Dr. Scanlon was the CEO/Co-Founder of Melanoma Diagnostics, acquired by Myriad in 2010, and a Vice President at Berlex/Schering AG, where he was responsible for the development of medical products for diagnostics and small molecule projects in Europe, ...

Rudolph Neri, 83 NorthJersey.com Born in South Barre, Mass., he came to Hawthorne in 1956 after graduating from Holy Cross College with a BA Degree and received his master's degree and Ph.D at New York University. He was employed at Schering Plough (now Merck) Pharmaceutical Co. as ...

Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug ... MarketWatch (press release) stated Chief Medical Officer of Kinex Pharmaceuticals, Dr. Rudolf Kwan, who was previously Vice-President of Clinical Research, at Schering-Plough Research Institute. Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, ... y más »

CORRECTING and REPLACING Tonix Pharmaceuticals Appoints Dr. Samuel ... MarketWatch (press release) Prior to joining ALZA Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks formerly served as a scientific advisor to ArQule Pharmaceuticals, CMEA Ventures and ProQuest Investments. y más »

Tonix Pharmaceuticals Appoints Dr. Samuel Saks to Its Board of ... MarketWatch (press release) Prior to joining ALZA Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks formerly served as a scientific advisor to ArQule Pharmaceuticals, CMEA Ventures and ProQuest Investments. y más »

XENETIC BIOSCIENCES PLC : - Appointment of VP for Drug Development 4-traders Dr Hoppe graduated with a Ph.D. in Genetic Toxicology from the Massachusetts Institute of Technology (MIT) in 1980 having first gained his Bachelors degree at MIT in 1973. Between 1980 and 1984, Dr Hoppe held positions at the Harvard Medical School and ... y más »

Tonix Pharmaceuticals Appoints Dr. Samuel Saks to Its Board of ... EON: Enhanced Online News (press release) Prior to joining ALZA Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks formerly served as a scientific advisor to ArQule Pharmaceuticals, CMEA Ventures and ProQuest Investments. y más »

Cynapsus Therapeutics Nominates New Directors for Board Healthcare Global (press release) Most of his career was spent at Abbott (17 years) although he has worked at Pharmacia, Oxford Bioscience Partners, Schering Plough and Merck. He has a strong track record of making significant contributions to company growth by closing transactions ... y más »

Jones Lang LaSalle Incorporated's CEO Discusses Q1 2012 Results ... Seeking Alpha Major leasing and tenant representation assignments completed during the quarter included a 355000 square foot lease in Dublin from Merck/Schering-Plough. LaSalle Investment Management continued to deliver strong performance for its clients during the ...